- Home
- HCI vs KURA Comparison
HCI vs KURA Comparison
Compare HCI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- KURA
- Stock Information
- Founded
- HCI 2006
- KURA 2014
- Country
- HCI United States
- KURA United States
- Employees
- HCI N/A
- KURA N/A
- Industry
- HCI Property-Casualty Insurers
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCI Finance
- KURA Health Care
- Exchange
- HCI Nasdaq
- KURA Nasdaq
- Market Cap
- HCI 1.2B
- KURA 1.3B
- IPO Year
- HCI N/A
- KURA N/A
- Fundamental
- Price
- HCI $107.99
- KURA $15.91
- Analyst Decision
- HCI Buy
- KURA Strong Buy
- Analyst Count
- HCI 5
- KURA 7
- Target Price
- HCI $140.00
- KURA $29.83
- AVG Volume (30 Days)
- HCI 142.4K
- KURA 799.4K
- Earning Date
- HCI 11-07-2024
- KURA 11-07-2024
- Dividend Yield
- HCI 1.48%
- KURA N/A
- EPS Growth
- HCI 163.93
- KURA N/A
- EPS
- HCI 11.94
- KURA N/A
- Revenue
- HCI $750,846,000.00
- KURA N/A
- Revenue This Year
- HCI N/A
- KURA N/A
- Revenue Next Year
- HCI $11.25
- KURA N/A
- P/E Ratio
- HCI $9.06
- KURA N/A
- Revenue Growth
- HCI 48.73
- KURA N/A
- 52 Week Low
- HCI $81.35
- KURA $9.06
- 52 Week High
- HCI $124.00
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- HCI 43.17
- KURA 35.15
- Support Level
- HCI $105.00
- KURA $15.55
- Resistance Level
- HCI $121.40
- KURA $16.68
- Average True Range (ATR)
- HCI 5.46
- KURA 1.02
- MACD
- HCI -1.20
- KURA -0.13
- Stochastic Oscillator
- HCI 17.28
- KURA 10.96
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are HCPCI insurance operations, TypTap Group, Real estate operations, and Corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.